Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;9(5):503-6.
doi: 10.1586/17476348.2015.1081064. Epub 2015 Aug 20.

CLCA1 and TMEM16A: the link towards a potential cure for airway diseases

Tom J Brett  1   2   3   4   5
Affiliations
Review

CLCA1 and TMEM16A: the link towards a potential cure for airway diseases

Tom J Brett. Expert Rev Respir Med. 2015 Oct.

Abstract

The hallmark traits of chronic obstructive airway diseases are inflammation, airway constriction due to hyperreactivity and mucus overproduction. The current common treatments for asthma and chronic obstructive pulmonary disease target the first two traits with none currently targeting mucus overproduction. The main source of obstructive mucus production is mucus cell metaplasia (MCM), the transdifferentiation of airway epithelial cells into mucus-producing goblet cells, in the small airways. Our current understanding of MCM is profusely incomplete. Few of the molecular players involved in driving MCM in humans have been identified and for many of those that have, their functions and mechanisms are unknown. This fact has limited the development of therapeutics that target mucus overproduction by inhibiting MCM. Current work in the field is aiming to change that.

Keywords: CLCA1; COPD; TMEM16A; asthma; calcium-activated chloride channel; mucus overproduction.

PubMed Disclaimer

Conflict of interest statement

Financial and competing interests disclosure

The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

References

    1. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiological reviews. 2006;86:245–278. - PubMed
    1. Thai P, Loukoianov A, Wachi S, Wu R. Regulation of airway mucin gene expression. Annual review of physiology. 2008;70:405–429. - PMC - PubMed
    1. Evans CM, Koo JS. Airway mucus: the good, the bad, the sticky. Pharmacology & therapeutics. 2009;121:332–348. - PMC - PubMed
    1. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2261–2263. - PMC - PubMed
    1. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–2261. - PubMed

MeSH terms